Latest News and Press Releases

HUDDINGE, Sweden, Feb. 7, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF) (Stockholm:KARO): -- A clinical development candidate was selected in July in the project with Merck & Co., Inc. for...

HUDDINGE, Sweden, Jan. 28, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF) has promoted Dr. Anders Berkenstam, Director R&D Sweden, to Vice President R&D Sweden and Dr. Paul Hamilton, Director...

HUDDINGE, Sweden, Oct. 16, 2002 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF): -- Significant preclinical milestone reached in the collaboration with Merck & Co., Inc. Milestone payment...

HUDDINGE, Sweden, Oct. 9, 2002 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF) (Stockholm:KARO) and Bristol-Myers Squibb Company (NYSE:BMY) have been collaborating for development of a new obesity...

HUDDINGE, Sweden, July 17, 2002 (PRIMEZONE) -- A significant preclinical milestone has been achieved in the estrogen receptor collaboration between Merck & Co., Inc and Karo Bio. The event is...

HUDDINGE, Sweden, July 16, 2002 (PRIMEZONE) -- Karo Bio: The partner projects continue to make progress in compound characterization for selection of clinical development candidates. The internal...

HUDDINGE, Sweden, May 16, 2002 (PRIMEZONE) -- Karo Bio, a leading international drug discovery company focusing on nuclear receptors as drug targets, will today present an overview of the Company for...

HUDDINGE, Sweden, April 26, 2002 (PRIMEZONE) -- Karo Bio: At Karo Bio AB's Annual General Meeting on April 25, 2002 the following was resolved. Dividend No dividend is to be paid for the...

HUDDINGE, Sweden, April 25, 2002 (PRIMEZONE) -- The Board of Directors of Karo Bio AB has decided to withdraw its proposal to the Annual General Meeting to introduce a Stock Option Program. Before...

HUDDINGE, Sweden, April 24, 2002 (PRIMEZONE) -- Karo Bio: -- Clinical development for the first obesity compound discontinued. The project continues and a program to replace the compound is...